Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.36 |
| ▸ | PDE4A | P27815 | 5/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12462410 | 0.90 | ADORA2B (0.40) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL1713209 | 0.90 | ADORA2B (0.40) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL563544 | 0.86 | ADORA2A (0.46) | ADORA2BADORA2AHTT | |
| SCHEMBL1712686 | 0.86 | ADORA2B (0.55) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| Trifluoroacetic Acid SCHEMBL1712829 | 0.83 | ADORA2B (0.35) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL1713144 | 0.81 | ADORA2B (0.36) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL1713215 | 0.79 | ADORA2A (0.46) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL1713244 | 0.76 | ADORA2A (0.41) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL2522523 | 0.75 | ADORA2A (0.46) | ADORA2BADORA2AHTT | |
| SCHEMBL1713126 | 0.73 | ADORA2B (0.39) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049544-B9 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2011-07-20 | — | — | EP | claimed |
| US-7902205-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-03-08 | — | — | US | claimed |
| EP-2049544-B1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2010-11-03 | — | — | EP | claimed |
| EP-2049544-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | Incyte Corporation (US) | 2009-04-22 | — | — | EP | claimed |
| US-20090088446-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2009-04-02 | — | — | US | claimed |
| US-20090076269-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2009-03-19 | — | — | US | claimed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | claimed |
| WO-2007150026-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | claimed |
| EP-2049544-B9 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2049544-B9 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7902205-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902205-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902205-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7863285-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7462624-B2 | Purinone derivatives as HM74a agonists | INCYTE CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007150026-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007150026-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088446-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | ADORA2B 68/4885ADORA2A 12/4885PDE4A 158/4885 |
| US-20090076269-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | ADORA2B 68/4885ADORA2A 12/4885PDE4A 158/4885 |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | ADORA2B 68/4885ADORA2A 12/4885PDE4A 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.